The NIH SBIR Regulatory Plan: What It Is, Who Needs One, and What Goes In It
Quick Answer
The NIH SBIR/STTR Regulatory Plan is a two page attachment, named RegulatoryPlan.pdf, that is required for any SBIR or STTR application proposing a clinical trial. It describes the regulatory pathway you are pursuing, the approvals needed to run the proposed trial, your interactions with FDA, and a dated milestone timeline. Applications that do not propose a clinical trial must not submit it.
That is the short answer. This is what NIH actually asks for, why reviewers weigh it more heavily than most founders expect, and a free template that maps to every requirement.
What is the NIH SBIR Regulatory Plan?
The Regulatory Plan is a standalone narrative attachment in the Other Attachments section of the Research and Related Other Project Information form. It is capped at two pages for the entire attachment, and the file must be named RegulatoryPlan.pdf.
It is not part of your Research Strategy and it is not your Commercialization Plan. It answers a narrower question: what regulatory clearance does this trial require, and do you know how to get it.
Who has to submit a Regulatory Plan?
You must include it if your application proposes a clinical trial under the NIH definition. You must not include it if your application does not propose a clinical trial.
This requirement appears in the parent SBIR and STTR clinical trial optional notices, the SBIR Phase IIB Strategic Breakthrough Award, and the SBIR/STTR Commercialization Readiness Pilot. Because the wording is repeated across NOFOs but not identical in every one, read your specific NOFO before you build the attachment. The NOFO always governs.
If you are unsure whether your aims meet NIH's clinical trial definition, resolve that first using NIH's clinical trial decision tree. Getting the determination wrong means either a missing required attachment or an attachment that should never have been submitted.
What does NIH require the plan to cover?
At minimum, the plan must address the regulatory requirements needed to conduct the proposed clinical trial. NIH strongly encourages, but does not strictly require, a discussion of the requirements for marketing approval.
Beyond that minimum, NIH asks applicants to:
Describe the regulatory pathway being pursued or planned, with a timeline to regulatory approval built on discrete milestones
Provide details of interactions with the appropriate regulatory authority, including the specific contact and the date of each interaction
Describe any outside assistance obtained or planned to develop and execute the plan
One detail founders routinely get wrong: the supporting evidence of those interactions, meaning letters, emails, and meeting minutes, is not submitted with the application. NIH may request it after submission, and it must be furnished on request. Attaching that correspondence to the application is a common and avoidable error.
Why founders applying to NIH SBIR need this attachment done well
Three reasons it carries weight beyond its two pages.
It is a completeness check. A required attachment that is missing, misnamed, or over the page limit creates administrative risk before your science is ever discussed. RegulatoryPlan.pdf is an exact filename requirement, not a suggestion.
Reviewers read it as evidence of feasibility. A trial that cannot legally start on the timeline in your Statement of Work is a scored weakness, no matter how strong the underlying science. Naming your pathway, your IND or IDE determination, and your IRB route shows the trial is executable in the project period.
It separates teams that have talked to FDA from teams that have not. A plan citing a specific pre-submission number and date reads very differently from one referencing ongoing dialogue with the agency. In two pages, specificity is the entire signal.
For deep tech and biomedical founders, the regulatory plan is also where a genuinely novel product gets to make its strongest argument. When no predicate or cleared alternative exists, stating that plainly is often the best available justification for a De Novo pathway or a breakthrough designation.
What the BW&CO Regulatory Plan Template covers
Our free template is built to the two page limit and structured in the order NIH expects. It includes eight sections, each with an instruction on what belongs there and a bracketed prompt to fill in:
Regulatory Objective and Product Overview, covering intended use and target pathway
Current Regulatory Landscape and Pathway Rationale, including product code and predicate analysis
Regulatory Requirements to Conduct the Proposed Clinical Trial, covering IND and IDE determination, the IRB and human subjects pathway, and other trial enabling requirements
Pathway to Marketing Approval, including expedited program status
Regulatory Authority Interactions, logged with dates, contacts, interaction types, and outcomes
Outside Regulatory Assistance
Regulatory Milestones and Timeline, tied to project months
Supporting Documentation Statement, the standing language confirming evidence is on file
It also includes a compliance summary covering the page limit, the required filename, and the exact form field, plus drafting tips drawn from plans we have prepared for funded applicants.
Common Regulatory Plan mistakes
Submitting the attachment when the application does not propose a clinical trial
Renaming the file to something other than RegulatoryPlan.pdf
Running past two pages, which is a hard cap for the entire attachment
Attaching FDA correspondence or meeting minutes that NIH did not ask for
Referring vaguely to agency contact without a submission number, contact, or date
Writing narrative prose instead of dated milestones tied to the Statement of Work
Spending the two pages on marketing approval while underserving the requirements to actually start the trial
Frequently asked questions
Is the Regulatory Plan required for every NIH SBIR application? No. It is required only for applications proposing a clinical trial. Applications that do not propose a clinical trial must not submit it.
What is the page limit for the NIH Regulatory Plan? Two pages maximum for the entire attachment.
What should the file be named? RegulatoryPlan.pdf, attached in the Other Attachments section of the Research and Related Other Project Information form.
Do I need to attach FDA correspondence as proof of our interactions? No. Letters, emails, and meeting minutes are not submitted with the application. Keep them on file and furnish them if the NIH awarding component requests them.
Do I need to have met with FDA before applying? It is not an absolute prerequisite, but documented interaction with the regulatory authority strengthens the plan considerably. Applicants may be asked to submit evidence that they contacted the authority and that their research plan follows its guidance.
Is the Regulatory Plan the same as the Commercialization Plan? No. The Commercialization Plan is a separate twelve page attachment required for Phase II, Direct to Phase II, Phase IIB, Fast Track, and CRP applications. The Regulatory Plan is two pages and is specific to clinical trial applications.
Does the Regulatory Plan apply to Phase IIB and CRP applications? Yes, the requirement appears in the Phase IIB Strategic Breakthrough and Commercialization Readiness Pilot notices as well. Always confirm against your specific NOFO.
Get the template, or get help
Download the BW&CO NIH SBIR/STTR Regulatory Plan Template and build the attachment section by section.
If you would rather have it reviewed, or you are still deciding whether your aims trigger NIH's clinical trial definition, our team has helped clients secure more than $350M in non-dilutive funding.